Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
- 13 August 2010
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 67 (6) , 1273-1279
Abstract
The primary objective of this sub-study, undertaken as an extension to the previously reported phase-I study, was to explore the feasibility, tolerability and pharmacokinetics (PK) of belinostat when administered by the oral route. Preliminary pharmacodynamic (PD) studies were also performed to enable comparison of the biological effects of the oral and intravenous formulations.Keywords
This publication has 13 references indexed in Scilit:
- Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008
- A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid TumorsClinical Cancer Research, 2008
- Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancerInternational Journal of Cancer, 2007
- A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced CancerClinical Cancer Research, 2006
- The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivoCancer Chemotherapy and Pharmacology, 2006
- Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studiesMolecular Cancer Therapeutics, 2006
- Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancerInvestigational New Drugs, 2006
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or LymphomaJournal of Clinical Oncology, 2005
- Acetylation control of the retinoblastoma tumour-suppressor proteinNature Cell Biology, 2001